| 000 | 01072 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250517032843.0 | ||
| 264 | 0 | _c20150901 | |
| 008 | 201509s 0 0 eng d | ||
| 022 | _a1474-5488 | ||
| 024 | 7 |
_a10.1016/S1470-2045(15)70190-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBlock, Matthew S | |
| 245 | 0 | 0 |
_aSecond-line dovitinib in metastatic endometrial cancer. _h[electronic resource] |
| 260 |
_bThe Lancet. Oncology _cJun 2015 |
||
| 300 |
_a604-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 | _aAntineoplastic Combined Chemotherapy Protocols |
| 650 | 0 | 4 |
_aBenzimidazoles _xadministration & dosage |
| 650 | 0 | 4 |
_aEndometrial Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aQuinolones _xadministration & dosage |
| 650 | 0 | 4 |
_aReceptor, Fibroblast Growth Factor, Type 2 _xgenetics |
| 700 | 1 | _aDowdy, Sean C | |
| 773 | 0 |
_tThe Lancet. Oncology _gvol. 16 _gno. 6 _gp. 604-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1470-2045(15)70190-7 _zAvailable from publisher's website |
| 999 |
_c24908179 _d24908179 |
||